ライフサイエンスコーパス: mineralocorticoid receptor

1 s sensitive to antagonism of GPER but not of mineralocorticoid receptor.

2 roate antagonism versus agonism in the human mineralocorticoid receptor.

3 nt PHAI is characterized by mutations in the mineralocorticoid receptor.

4 ediated in part by aldosterone acting on the mineralocorticoid receptor.

5 progesterone-mediated activation of a mutant mineralocorticoid receptor.

6 icating that aldosterone was working via the mineralocorticoid receptor.

7 cocorticoid receptor, estrogen receptor, and mineralocorticoid receptor.

8 d is vital for dictating specificity for the mineralocorticoid receptor.

9 id receptor, they also bind and activate the mineralocorticoid receptor.

10 an be remedied by blocking activation of the mineralocorticoid receptor.

11 t cell line that stably expresses functional mineralocorticoid receptors.

12 owing aldosterone occupancy of cardiomyocyte mineralocorticoid receptors.

13 emide effect can be prevented by blockade of mineralocorticoid receptors.

14 binding to and activating glucocorticoid and mineralocorticoid receptors.

15 result of cortisol depletion of the cerebral mineralocorticoid receptors.

16 The glucocorticoid receptor and the mineralocorticoid receptor, 2 glucocorticoid-binding rec

17 However, obesity also causes mineralocorticoid receptor activation independent of ald

18 through transcriptional mechanisms involving mineralocorticoid receptor activation.

19 In addition to acting on mineralocorticoid receptors, aldosterone has been recent

20 Estrogen receptor alpha and mineralocorticoid receptor also contain functional NES,

21 um, whereas expression of mRNAs encoding the mineralocorticoid receptor and 11beta-HSD type 2 was hig

22 , tumor necrosis factor-alpha decreased both mineralocorticoid receptor and alpha1-adrenoceptor expre

23 harmacological studies and demonstrated both mineralocorticoid receptor and glucocorticoid receptor p

24 pendent nuclear translocation and binding of mineralocorticoid receptor and glucocorticoid receptor t

25 These neurons express mineralocorticoid receptors and the enzyme 11-beta-hydro

26 es specific for the glucocorticoid receptor, mineralocorticoid receptor, and 11beta-HSD types 1 and 2

27 sues mRNAs encoding glucocorticoid receptor, mineralocorticoid receptor, and 11beta-HSD types 1 and 2

28 gen receptor alpha, glucocorticoid receptor, mineralocorticoid receptor, and progesterone receptor) a

29 addition of aldosterone, is mediated through mineralocorticoid receptors, and does not require de nov

30 treatment of patients with a combination of mineralocorticoid receptor antagonism (eplerenone) and a

31 mechanistic investigations have established mineralocorticoid receptor antagonism as the new treatme

32 Therefore, central mineralocorticoid receptor antagonism could increase com

33 ological changes do not readily reverse with mineralocorticoid receptor antagonism in adulthood.

34 le that, along with ACE-I and beta-blockers, mineralocorticoid receptor antagonism will become part o

35 In human pulmonary artery endothelial cells, mineralocorticoid receptor antagonism with spironolacton

36 Mineralocorticoid receptor antagonism, but not PAI-1 def

37 receptor antagonist pretreatment and not by mineralocorticoid receptor antagonism, suggesting a gluc

38 fine better the biologic mechanisms by which mineralocorticoid receptor antagonisms exert the observe

39 nd renal function in patients treated with a mineralocorticoid receptor antagonist (MRA).

40 tics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist (yes/no),and defib

41 Here we demonstrate that spironolactone, a mineralocorticoid receptor antagonist approved for clini

42 e intestinal peptide receptor 2, and a novel mineralocorticoid receptor antagonist are in phase II/II

43 We evaluated the effect of the selective mineralocorticoid receptor antagonist eplerenone on rena

44 lopment of CV injury were assessed using the mineralocorticoid receptor antagonist spironolactone (0,

45 The mineralocorticoid receptor antagonist spironolactone inh

46 We show here that the mineralocorticoid receptor antagonist spironolactone red

47 adding an angiotensin receptor blocker or a mineralocorticoid receptor antagonist to a regimen based

48 n angiotensin-converting enzyme inhibitor or mineralocorticoid receptor antagonist was associated wit

49 angiotensin-converting enzyme inhibitor or a mineralocorticoid receptor antagonist will decrease the

50 ementing HK-fed Kcnmb1(-/-) with eplerenone (mineralocorticoid receptor antagonist) corrected the flu

51 In addition, 4671 (56%) were treated with a mineralocorticoid receptor antagonist, 2539 (30%) with d

52 These changes were prevented by the mineralocorticoid receptor antagonist, spironolactone.

53 We assessed the risk factors for mineralocorticoid receptor antagonist-related WRF and fo

54 rein all patients with RH are treated with a mineralocorticoid-receptor antagonist without further te

55 ngiotensin II receptor blockers (84.2%), and mineralocorticoid receptor antagonists (57.0%).

56 Mineralocorticoid receptor antagonists (MRA) improve out

57 Mineralocorticoid receptor antagonists (MRA) reduce morb

58 receptor blockers (ARB), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and angiot

59 Consensus guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) for select

60 Mineralocorticoid receptor antagonists (MRAs) have becom

61 Mineralocorticoid receptor antagonists (MRAs) may attenu

62 The mineralocorticoid receptor antagonists (MRAs) spironolac

63 Mineralocorticoid receptor antagonists administered at h

64 Mineralocorticoid receptor antagonists are a valuable ad

65 These findings suggest that the use of mineralocorticoid receptor antagonists coupled with GC t

66 Mineralocorticoid receptor antagonists improve outcomes

67 ace, but whether race influences efficacy of mineralocorticoid receptor antagonists in heart failure

68 findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by rac

69 The incidence of hyperkalemia caused by mineralocorticoid receptor antagonists may vary by race,

70 rimary objective was to assess the impact of mineralocorticoid receptor antagonists on cardiovascular

71 Mineralocorticoid receptor antagonists reduce morbidity

72 zed controlled trials in heart failure (HF), mineralocorticoid receptor antagonists reduced mortality

73 Mineralocorticoid receptor antagonists were independentl

74 Mineralocorticoid receptor antagonists were prescribed i

75 ism (e.g., thiazide-type diuretic agents and mineralocorticoid receptor antagonists) should be avoide

76 receptor blockers (ARBs), beta blockers, and mineralocorticoid receptor antagonists, and advanced dev

77 ors, Ang II type 1 receptor antagonists, and mineralocorticoid receptor antagonists, are a cornerston

78 , N-terminal pro-B-type natriuretic peptide, mineralocorticoid receptor antagonists, low voltage, ine

79 antagonist G-36, but was not affected by the mineralocorticoid receptor antagonists, spironolactone a

80 g body of evidence has suggested benefits of mineralocorticoid receptor antagonists, such as eplereno

81 Mineralocorticoid receptor antagonists, such as spironol

82 ocked by the GPER antagonist, but not by the mineralocorticoid receptor antagonists.

83 rolytes in patients with AF and HF receiving mineralocorticoid receptor antagonists.

84 with heart failure and may be attenuated by mineralocorticoid receptor antagonists.

85 eta-blockers, and 32% (95% CI: 25%-39%) with mineralocorticoid receptor antagonists.

86 Mineralocorticoid-receptor antagonists improve the progn

87 tensin-receptor blockers, beta-blockers, and mineralocorticoid-receptor antagonists.

88 nne muscular dystrophy mouse models and that mineralocorticoid receptors are present and functional i

89 Because cardiac mineralocorticoid receptors are protected from mineraloc

90 In contrast, an antagonist of the mineralocorticoid receptor as well as agonists of proges

91 tin, estrogen, androgen, glucocorticoid, and mineralocorticoid receptor, as well as sex hormone and c

92 confirmed the presence of glucocorticoid and mineralocorticoid receptors at these sites.

93 Although we have known that mineralocorticoid receptor blockade attenuates cardiovas

94 Mineralocorticoid receptor blockade before stress preven

95 Mineralocorticoid receptor blockade blunted leptin-induc

96 angiotensin-converting enzyme inhibition nor mineralocorticoid receptor blockade decreased the primar

97 l injury, only recently have we learned that mineralocorticoid receptor blockade improves pancreatic

98 Mineralocorticoid receptor blockers have been shown to b

99 genetic causes of primary aldosteronism, and mineralocorticoid receptor blockers have now become an i

100 needs to be achieved in exploring the use of mineralocorticoid receptor blockers in less advanced sta

101 attributed to promiscuous activation of the mineralocorticoid receptor by cortisol, thereby promotin

102 2), allowing inappropriate activation of the mineralocorticoid receptor by endogenous glucocorticoid.

103 of inappropriate activation of cardiomyocyte mineralocorticoid receptors by aldosterone and reveal a

104 SD2 is inhibited and may allow access to the mineralocorticoid receptors by glucocorticoids.

105 Consistently, blockade of mineralocorticoid receptors by spironolactone treatment

106 Although aldosterone, acting via mineralocorticoid receptors, causes left ventricular (LV

107 excess, in which cortisol illicitly occupies mineralocorticoid receptors, causing hypertension and hy

108 (SAME), in which cortisol illicitly occupies mineralocorticoid receptors, causing sodium retention, h

109 id receptor did not, and studies with rat GR-mineralocorticoid receptor chimeras confirmed that the G

110 tructure and function, oxidative stress, and mineralocorticoid receptor-dependent gene transcription

111 d ejection fraction independently of classic mineralocorticoid receptor-dependent gene transcription.

112 across the groups but no evidence of classic mineralocorticoid receptor-dependent gene transcription.

113 uses cardiovascular and renal injury through mineralocorticoid receptor-dependent mechanisms.

114 ressure response to dietary sodium through a mineralocorticoid receptor-dependent pathway.

115 repressed TGF-beta transactivation, whereas mineralocorticoid receptor did not, and studies with rat

116 ucocorticoid synthesis or glucocorticoid and mineralocorticoid receptors enabled the expression of em

117 roid hormone aldosterone and its partner the mineralocorticoid receptor-evolved by a stepwise Darwini

118 Furthermore, blunted vascular mineralocorticoid receptor expression might participate

119 Mineralocorticoid receptor expression was also blunted i

120 Both alpha1-adrenoceptor and mineralocorticoid receptor expressions studied in mouse

121 cause PHA1, underscore the important role of mineralocorticoid receptor function in regulation of sal

122 d by a persistent enhancement in hippocampal mineralocorticoid receptor function.

123 ralocorticoid receptor, we have screened the mineralocorticoid receptor gene (MLR) for variants and h

124 Mutations in the mineralocorticoid receptor gene (MR) cause adPHA1, but t

125 netic evidence is against involvement of the mineralocorticoid receptor gene, MLR, in PHA1.

126 , Na/H and anion exchangers, E-cadherin, and mineralocorticoid receptor genes as well as genes for th

127 The glucocorticoid and mineralocorticoid receptors (GR and MR) share considerab

128 -jun, which forms a nuclear complex with the mineralocorticoid receptor in a kidney fibroblast cell l

129 enetic study support a possible role for the mineralocorticoid receptor in the pathogenesis of cCSC.

130 le is known about the role of aldosterone or mineralocorticoid receptors in mediating adverse remodel

131 agonist eplerenone (EPL) to test the role of mineralocorticoid receptors in mediating the transition

132 locorticoids and the involvement of vascular mineralocorticoid receptors in murine endotoxic and huma

133 ss of aldosterone to otherwise non-selective mineralocorticoid receptors in the distal nephron.

134 Mineralocorticoid receptors in the inner medullary colle

135 glucocorticoids from otherwise nonselective mineralocorticoid receptors in the kidney.

136 e replacement suggests that occupancy of the mineralocorticoid receptor is responsible for the steroi

137 This study assessed whether the mineralocorticoid receptor iso/val polymorphism (rs5522)

138 e recently discovered interaction of GC with mineralocorticoid receptors may counteract negative effe

139 one stimulates fibronectin synthesis through mineralocorticoid receptor (MCR) dependent activation of

140 rone (B), suggesting glucocorticoid (but not mineralocorticoid) receptor-mediated repression.

141 e receptors-2 mGlu2, neuropeptide-Y NPY, and mineralocorticoid receptors MR).

142 Here we show that mineralocorticoid receptor (MR) activation by aldosteron

143 erations in glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) activation drive compuls

144 dent aldosteronism that results in excessive mineralocorticoid receptor (MR) activation.

145 g is the first step in hormone regulation of mineralocorticoid receptor (MR) activity.

146 with hormone replacement with the selective mineralocorticoid receptor (MR) agonist aldosterone, the

147 the steroid hormone aldosterone, which is a mineralocorticoid receptor (MR) agonist, is associated w

148 receptor protein expression as determined by mineralocorticoid receptor (MR) and glucocorticoid recep

149 mRNA; in hippocampal CA1, a reduction of the mineralocorticoid receptor (MR) and GR was observed.

150 Because adipocytes express mineralocorticoid receptor (MR) and MR blockade reduces

151 l function are thought to be mediated by the mineralocorticoid receptor (MR) and the glucocorticoid r

152 In rodents, mineralocorticoid receptor (MR) antagonism prevents AKI

153 ly, renin-angiotensin-aldosterone system and mineralocorticoid receptor (MR) antagonism reduces cardi

154 the administration of the novel nonsteroidal mineralocorticoid receptor (MR) antagonist BR-4628 can p

155 , was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro pote

156 ion, or that were treated with the selective mineralocorticoid receptor (MR) antagonist spironolacton

157 rofibrotic effects, respectively, as did the mineralocorticoid receptor (MR) antagonist spironolacton

158 The mineralocorticoid receptor (MR) antagonist spironolacton

159 Administration of the mineralocorticoid receptor (MR) antagonist spironolacton

160 n converting enzyme inhibitor lisinopril and mineralocorticoid receptor (MR) antagonist spironolacton

161 mortality has led to increased interest in a mineralocorticoid receptor (MR) antagonist-based treatme

162 Mineralocorticoid receptor (MR) antagonists are the reco

163 Steroidal mineralocorticoid receptor (MR) antagonists are used for

164 FDA-approved mineralocorticoid receptor (MR) antagonists are used to

165 A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified a

166 cal and experimental studies have shown that mineralocorticoid receptor (MR) antagonists substantiall

167 These effects were dependent on the mineralocorticoid receptor (MR) as they were abolished b

168 e aim of this study was to determine whether mineralocorticoid receptor (MR) blockade improves CFR in

169 as a deleterious hormone in the heart, with mineralocorticoid receptor (MR) blockade reducing mortal

170 TRPM7 current was inhibited by eplerenone, a mineralocorticoid receptor (MR) blocker, and GSK-650394,

171 Spironolactone, a nonselective mineralocorticoid receptor (MR) blocker, antagonizes ald

172 tective effects of Ly, a novel non-steroidal mineralocorticoid receptor (MR) blocker, through two exp

173 Mineralocorticoid receptor (MR) controls sodium homeosta

174 ects on GR or TH expression in the VTA or on mineralocorticoid receptor (MR) expression in any of the

175 Mineralocorticoid receptor (MR) expression is increased

176 s shift may be mediated by activation of the mineralocorticoid receptor (MR) for cortisol.

177 s by protecting the inherently non-selective mineralocorticoid receptor (MR) from occupancy by endoge

178 ects of ANP and its second messenger cGMP on mineralocorticoid receptor (MR) function in rat colon su

179 1 mice also unexpectedly exhibited increased mineralocorticoid receptor (MR) gene expression.

180 sults on the subcellular localization of the mineralocorticoid receptor (MR) have been controversial.

181 After a survey of the entire brain for mineralocorticoid receptor (MR) immunoreactivity, we dis

182 and anxiety disorders, the role of the brain mineralocorticoid receptor (MR) in stress, depression, a

183 We studied the role of the mineralocorticoid receptor (MR) in the signaling that pr

184 Here, we targeted the role of the mineralocorticoid receptor (MR) in the stress-induced mo

185 esized that there is local expression of the mineralocorticoid receptor (MR) in the vasculature and t

186 The mineralocorticoid receptor (MR) is a hormone-dependent r

187 The mineralocorticoid receptor (MR) mediates the Na(+)-retai

188 Relative to the low level of GR, mineralocorticoid receptor (MR) mRNA and protein express

189 Phosphorylation of human mineralocorticoid receptor (MR) on Ser-843, a residue pl

190 trogen receptor alpha (ERalpha), but not the mineralocorticoid receptor (MR) or ERbeta.

191 In contrast, aldosterone and the mineralocorticoid receptor (MR) primarily promote cardio

192 rials have emphasized the beneficial role of mineralocorticoid receptor (MR) signaling blockade in he

193 s thought to be caused by an exacerbation of mineralocorticoid receptor (MR) signaling, given that it

194 f nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent pote

195 Both stereoisomers bind to the mineralocorticoid receptor (MR) with a Ki value of appro

196 coid response [glucocorticoid receptor (GR), mineralocorticoid receptor (MR), 11beta-hydroxysteroid d

197 d hormone aldosterone acts by binding to the mineralocorticoid receptor (MR), a ligand activated tran

198 d hormone aldosterone acts by binding to the mineralocorticoid receptor (MR), a ligand-activated tran

199 gulates sodium homeostasis by activating the mineralocorticoid receptor (MR), a member of the nuclear

200 The mineralocorticoid receptor (MR), acting in the kidney, i

201 y cultures demonstrated specific GR, but not mineralocorticoid receptor (MR), activation and phosphor

202 r beta (Esr2), glucocorticoid receptor (Gr), mineralocorticoid receptor (Mr), and progesterone recept

203 receptor (ER), glucocorticoid receptor (GR), mineralocorticoid receptor (MR), and progesterone recept

204 luding the glucocorticoid receptor (GR), the mineralocorticoid receptor (MR), corticotropin-releasing

205 aggravate CSCR and are known to bind to the mineralocorticoid receptor (MR), CSCR may be related to

206 We describe a mutation in the mineralocorticoid receptor (MR), S810L, that causes earl

207 affect the overall transcription of CRH, the mineralocorticoid receptor (MR), the serotonin transport

208 nsequence of mutations in genes encoding the mineralocorticoid receptor (MR), the three subunits of t

209 characterize the role of Rac1 GTPase for the mineralocorticoid receptor (MR)-mediated pro-fibrotic re

210 Although spironolactone can act at the mineralocorticoid receptor (MR; NR3C2), there is increas

211 xis occurs through a dual-receptor system of mineralocorticoid receptors (MR) and glucocorticoid rece

212 ression of glucocorticoid receptors (GR) and mineralocorticoid receptors (MR).

213 3C1 (glucocorticoid receptor; GR) and NR3C2 (mineralocorticoid receptor; MR) that encode for GRs and

214 Hippocampal mineralocorticoid receptor mRNA expression was increased

215 on of glucocorticoid hormones, which bind to mineralocorticoid receptors (MRs) and glucocorticoid rec

216 termine which brain receptors [high-affinity mineralocorticoid receptors (MRs) or low-affinity glucoc

217 Blocking brain mineralocorticoid receptors (MRs) reduces the high circu

218 Aldosterone activates mineralocorticoid receptors (MRs) to increase epithelial

219 a steroid hormone that signals through renal mineralocorticoid receptors (MRs) to regulate blood pres

220 chanism by which glucocorticoids, acting via mineralocorticoid receptors (MRs), decrease resilience t

221 and fluid homeostasis through binding to the mineralocorticoid receptors (MRs).

222 s in the glucocorticoid receptor (NR3C1) and mineralocorticoid receptor (NR3C2) genes with cCSC.

223 Predominant mineralocorticoid receptor occupation (ADC-LO group) res

224 ype b receptor, angiotensin type 1 receptor, mineralocorticoid receptor, or Nox isoforms 1 to 4.

225 its antitumor effects are independent of the mineralocorticoid receptor pathway.

226 Vascular mineralocorticoid receptors play a role in vascular tone

227 Mineralocorticoid receptors play an important role in me

228 ndent of blood pressure, but the role of the mineralocorticoid receptor remains unclear.

229 esource, the Androgen Receptor Resource, the Mineralocorticoid Receptor Resource, the Vitamin D Recep

230 We used the mineralocorticoid receptor-selective antagonist eplereno

231 sequences of aldosterone excess require full mineralocorticoid receptor signaling.

232 The effects of mineralocorticoid receptor stimulation are associated wi

233 ENaC transcription independent of effects on mineralocorticoid receptor trans-activation.

234 uate aldosterone activation of cardiomyocyte mineralocorticoid receptors, transgenic mice overexpress

235 histochemical analysis of glucocorticoid and mineralocorticoid receptors using monoclonal antibodies

236 ng to Nguyen et al., local inhibition of the mineralocorticoid receptor via antagonists (spironolacto

237 eroid hormone aldosterone acting through the mineralocorticoid receptor, we have screened the mineral

238 ne is rapid, aldosterone binds to a specific mineralocorticoid receptor which then triggers gene acti

239 Finally, antagonism of the mineralocorticoid receptor will attenuate or abrogate ma

240 nfirmed by pharmacological inhibition of the mineralocorticoid receptor with spironolactone or eplere

241 on of glucocorticoid receptors with RU486 or mineralocorticoid receptors with spironolactone caused u